Gout

Pegloticase Use for Uncontrolled Gout in the Dialysis Population Described

New study is the first to characterize pegloticase use in the dialysis population.

Comorbidity Onset, Not Flare Patterns, Vary Among Morbidity Clusters in Patients With Gout

Researchers evaluated the onset of comorbidities and flare patterns, based on baseline comorbidity clusters in patients with gout.

Pegloticase Immunogenicity Reduced With Concomitant Mycophenolate Mofetil Use in Refractory Gout

Researchers evaluated the effect of mycophenolate mofetil on the efficacy of pegloticase in patients with refractory gout.

Gout and Hyperuricemia Have Distinct Serum Metabolomic Signatures

Researchers studied metabolic alterations and dysregulated metabolic pathways in hyperuricemia and gout, and discovered potential metabolite biomarkers to differentiate between gout and asymptomatic hyperuricemia.

Genetic Prevalence of Traits Linked to Hyperuricemia, Gout, and Associated Comorbidities

Researchers tested the hypothesis that the association of traits representing hyperuricemia and its comorbidities is genetically based.

Clinician Q&A: Can Immunomodulators Improve the Effect of Pegloticase in Uncontrolled Gout?

Robert T. Keenan, MD, discusses the role of co-treatment with immunomodulators and pegloticase in patients with uncontrolled gout.

Increase in In-Hospital Cardiac Procedures for Patients With Gout, RA

Rates of in-hospital cardiac procedures continued to increase in people with gout and rheumatoid arthritis (RA) from 1998 to 2014.

Fenofibrate-Associated Nephrotoxicity Common in Patients With Gout

Researchers assessed the incidence and potential risk factors for the development offenofibrate-associated nephrotoxicity in patients with gout.

Weight Change Patterns During Adulthood Associated With Incident Gout

Researchers investigated the association between weight change patterns during adulthood and incident gout.

No Significant Effect of Elevated Urate on Bone Turnover Markers in Older Women

Researchers assessed the effect of hyperuricemia, induced by inosine supplementation, on bone turnover markers in postmenopausal women during a 6-month period.